1. Home
  2. BMEA vs TOUR Comparison

BMEA vs TOUR Comparison

Compare BMEA & TOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.03

Market Cap

96.9M

Sector

Health Care

ML Signal

HOLD

Logo Tuniu Corporation

TOUR

Tuniu Corporation

HOLD

Current Price

$0.75

Market Cap

87.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
TOUR
Founded
2017
2006
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Transportation Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
96.9M
87.0M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
BMEA
TOUR
Price
$1.03
$0.75
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$8.71
N/A
AVG Volume (30 Days)
1.2M
118.9K
Earning Date
11-04-2025
12-05-2025
Dividend Yield
N/A
4.93%
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
$75,532,120.00
Revenue This Year
N/A
$12.27
Revenue Next Year
N/A
$10.18
P/E Ratio
N/A
$21.97
Revenue Growth
N/A
7.57
52 Week Low
$0.87
$0.70
52 Week High
$7.46
$1.17

Technical Indicators

Market Signals
Indicator
BMEA
TOUR
Relative Strength Index (RSI) 34.94 42.33
Support Level $0.87 $0.70
Resistance Level $1.12 $0.77
Average True Range (ATR) 0.09 0.04
MACD 0.00 0.00
Stochastic Oscillator 27.93 38.91

Price Performance

Historical Comparison
BMEA
TOUR

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About TOUR Tuniu Corporation

Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.

Share on Social Networks: